Analysts Set Telix Pharmaceuticals Limited (NASDAQ:TLX) Price Target at $20.40

Telix Pharmaceuticals Limited (NASDAQ:TLX) has been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $20.40.

Several brokerages have weighed in on TLX. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. Citigroup dropped their target price on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Friday, July 17th. Finally, Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares during the period. XTX Topco Ltd bought a new stake in shares of Telix Pharmaceuticals during the 4th quarter valued at about $89,000. XY Capital Ltd bought a new stake in shares of Telix Pharmaceuticals during the 1st quarter valued at about $120,000. Finally, IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the second quarter worth about $213,000.

Telix Pharmaceuticals Trading Up 1.8%

Shares of NASDAQ:TLX opened at $12.00 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The company has a fifty day simple moving average of $10.55 and a 200 day simple moving average of $9.43. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $12.60.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.